Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + bevacizumab as second-line therapy for advanced/recurrent endometrial cancer
ChiCTR2100042265Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab and bevacizumab in endometrial cancer (EC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective Response Rate. Started Apr 2021; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2100042265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042265.